Casdin Partners Master Fund, L.P. has bought stock on 24 days since May 2020
10% owner at BioLife Solutions, Inc., and 4 other companies
SEC CIK 0001534265 · Filings on SEC.gov ↗
Casdin Partners Master Fund, L.P.'s record
3 months after each buy, from the first price a copier could get.
19 buys since 2020 with 3 months of prices.
Companies
Every filing
27 filings since May 2020, newest first
Biolife Solutions Inc
10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Standard Biotools Inc.
Director and 10% owner
Biolife Solutions Inc
10% owner
Biolife Solutions Inc
10% owner
Maxcyte, Inc.
10% owner
Maxcyte, Inc.
10% owner
Tenaya Therapeutics, Inc.
10% owner
Maxcyte, Inc.
10% owner
Decibel Therapeutics, Inc.
10% owner
Biolife Solutions Inc
10% owner
Biolife Solutions Inc
10% owner
Biolife Solutions Inc
10% owner
About Casdin Partners Master Fund, L.P.
Casdin Partners Master Fund, L.P. is a Delaware-incorporated investment fund (EIN: 770513190) focused on the life sciences sector, including healthcare, biotechnology, synthetic biology, and related technologies.( Headquartered at Walker House, 87 Mary Street, George Town, Cayman Islands, it operates as part of the Casdin Capital ecosystem, which invests in companies leveraging molecular information for innovation in diagnostics, precision therapies, genomics, and data platforms.(
The fund serves as a Director and 10% Owner of Standard BioTools Inc. (LAB), holding approximately 91,684,918 shares as of recent filings, with notable transactions including purchases and awards in 2024.( It has a history of active investments as a 10% Owner or Director in biotech firms such as BioLife Solutions (BLFS), GeneDx Holdings (WGS), MaxCyte (MXCT), and others, reflecting a strategy of building significant positions in high-growth life sciences companies.( Eli Casdin, managing member of the associated Casdin entity and general partner, oversees its investment advisory activities.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.